Fatal Rhizopus Pneumonia in Allogeneic Stem Cell Transplant Patients Despite Posaconazole Prophylaxis: Two Cases and Review of the Literature

Biology of Blood and Marrow Transplantation

Volumn 15, Issue 8, 2009, Pages 991-995

  Lekakis, Lazaros J ^a   Lawson, Amber ^a   Prante, Jeanette ^b   Ribes, Julie ^b   Davis, Gregory J ^b   Monohan, Gregory ^a   Baraboutis, Ioannis G ^c   Skoutelis, Athanasios T ^c   Howard, Dianna S ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

^c EVANGELISMOS HOSPITAL   (Greece)

Author keywords

BMT; GVHD; Mucorales; Posaconazole; Rhizopus

Indexed keywords

ALEMTUZUMAB; AMPHOTERICIN B LIPID COMPLEX; ANTIINFECTIVE AGENT; BUSULFAN; CYCLOPHOSPHAMIDE; FLUDARABINE; FOSCARNET; GANCICLOVIR; IMMUNOGLOBULIN; INFLIXIMAB; MELPHALAN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; POSACONAZOLE; STEROID; TACROLIMUS; VORICONAZOLE;

ACUTE GRAFT VERSUS HOST DISEASE; ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; AUTOPSY; CANCER GROWTH; CANCER RESISTANCE; CASE REPORT; CHRONIC GRAFT VERSUS HOST DISEASE; CYTOMEGALOVIRUS INFECTION; DEATH; DRUG TREATMENT FAILURE; FOLLICULAR LYMPHOMA; HUMAN; HUMAN TISSUE; INFECTION PREVENTION; LUNG LAVAGE; MALE; MINIMUM INHIBITORY CONCENTRATION; MUCORALES; NONHUMAN; PNEUMONIA; REDUCED INTENSITY CONDITIONING; RHIZOPUS; RNA VIRUS INFECTION; T CELL LYMPHOMA;

ANTIFUNGAL AGENTS; CHEMOPREVENTION; FATAL OUTCOME; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; MUCORMYCOSIS; PNEUMONIA; RHIZOPUS; TRANSPLANTATION, HOMOLOGOUS; TRIAZOLES;

EID: 67649604583     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2009.04.007     Document Type: Article

References (34)

1. Rachwalski E.J., Wieczorkiewicz J.T., and Scheetz M.H. Posaconazole: an oral triazole with an extended spectrum of activity. Ann Pharmacother 42 (2008) 1429-1438
2. Cornely O.A., Maertens J., Winston D.J., et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 356 (2007) 348-359
3. Ullmann A.J., Lipton J.H., Vesole D.H., et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med 356 (2007) 335-347
4. Wingard J.R., Carter S.L., Walsh T.J., et al. Results of a randomized, double-blind trial of fluconazole (FLU) vs. voriconazole (VORI) for the prevention of invasive fungal infections (IFI) in 600 allogeneic blood and marrow transplant (BMT) patients. Blood 110 (2007) 55a-56a
5. Chamilos G., Marom E.M., Lewis R.E., Lionakis M.S., and Kontoyiannis D.P. Predictors of pulmonary zygomycosis versus invasive pulmonary aspergillosis in patients with cancer. Clin Infect Dis 41 (2005) 60-66
6. Trifilio S.M., Bennett C.L., Yarnold P.R., et al. Breakthrough zygomycosis after voriconazole administration among patients with hematologic malignancies who receive hematopoietic stem-cell transplants or intensive chemotherapy. Bone Marrow Transplant 39 (2007) 425-429
7. Espinel-Ingroff A., Fothergill A., Ghannoum M., et al. Quality control and reference guidelines for CLSI broth microdilution susceptibility method (M 38-A document) for amphotericin B, itraconazole, posaconazole, and voriconazole. J Clin Microbiol 43 (2005) 5243-5246
8. Ullmann A.J., Cornely O.A., Burchardt A., et al. Pharmacokinetics, safety, and efficacy of posaconazole in patients with persistent febrile neutropenia or refractory invasive fungal infection. Antimicrob Agents Chemother 50 (2006) 658-666
9. Krishna G., Sansone-Parsons A., Martinho M., Kantesaria B., and Pedicone L. Posaconazole plasma concentrations in juvenile patients with invasive fungal infection. Antimicrob Agents Chemother 51 (2007) 812-818
10. Krishna G., Martinho M., Chandrasekar P., Ullmann A.J., and Patino H. Pharmacokinetics of oral posaconazole in allogeneic hematopoietic stem cell transplant recipients with graft-versus-host disease. Pharmacotherapy 27 (2007) 1627-1636
11. Sun Q.N., Fothergill A.W., McCarthy D.I., Rinaldi M.G., and Graybill J.R. In vitro activities of posaconazole, itraconazole, voriconazole, amphotericin B, and fluconazole against 37 clinical isolates of zygomycetes. Antimicrob Agents Chemother 46 (2002) 1581-1582
12. Sun Q.N., Najvar L.K., Bocanegra R., Loebenberg D., and Graybill J.R. In vivo activity of posaconazole against Mucor spp. in an immunosuppressed-mouse model. Antimicrob Agents Chemother 46 (2002) 2310-2312
13. Skiest D.J., Vazquez J.A., Anstead G.M., et al. Posaconazole for the treatment of azole-refractory oropharyngeal and esophageal candidiasis in subjects with HIV infection. Clin Infect Dis 44 (2007) 607-614
14. Greenberg R.N., Mullane K., van Burik J.A., et al. Posaconazole as salvage therapy for zygomycosis. Antimicrobial Agents Chemother 50 (2006) 126-133
15. van Burik J.A., Hare R.S., Solomon H.F., Corrado M.L., and Kontoyiannis D.P. Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases. Clin Infect Dis 42 (2006) e61-e65
16. Tobon A.M., Arango M., Fernandez D., and Restrepo A. Mucormycosis (zygomycosis) in a heart-kidney transplant recipient: recovery after posaconazole therapy. Clin Infect Dis 36 (2003) 1488-1491
17. Peel T., Daffy J., Thursky K., Stanley P., and Buising K. Posaconazole as first line treatment for disseminated zygomycosis. Mycoses 51 (2008) 542-545
18. Kok J., Gilroy N., Halliday C., et al. Early use of posaconazole in the successful treatment of rhino-orbital mucormycosis caused by Rhizopus oryzae. J Infection 55 (2007) e33-e36
19. Rutar T., and Cockerham K.P. Periorbital zygomycosis (mucormycosis) treated with posaconazole. Am J Ophthalmol 142 (2006) 187-188
20. Sedlacek P., Vavra V., Masova I., et al. Successful therapy with ABLC, surgery and posaconazole for Rhizopus microsporus var. rhizopodiformis liver eumycetoma in a child with acute leukaemia. Mycoses 52 (2008) 276-279
21. Stark D., Milliken S., Marriott D., and Harkness J. Rhizopus microsporus var. rhizopodiformis sinus-orbital zygomycosis in an immunosuppressed patient: successful treatment with posaconazole after a complicated clinical course. J Med Microbiol 56 (2007) 699-701
22. Gilman A.L., Serrano A., Skelley J., and Zwick D. Successful treatment of pulmonary zygomycosis with posaconazole in a recipient of a haploidentical donor stem cell transplant. Pediatr Blood Cancer 47 (2006) 959-963
23. Arikan S., Sancak B., Alp S., Hascelik G., and McNicholas P. Comparative in vitro activities of posaconazole, voriconazole, itraconazole, and amphotericin B against Aspergillus and Rhizopus, and synergy testing for. Rhizopus. Med Mycol (2008) 1-7
24. Perkhofer S., Locher M., Cuenca-Estrella M., et al. Posaconazole enhances the activity of amphotericin B against hyphae of zygomycetes in vitro. Antimicrob Agents Chemother 52 (2008) 2636-2638
25. Dannaoui E., Meletiadis J., Mouton J.W., Meis J.F., and Verweij P.E. In vitro susceptibilities of zygomycetes to conventional and new antifungals. J Antimicrob Chemother 51 (2003) 45-52
26. Rodriguez M.M., Serena C., Marine M., Pastor F.J., and Guarro J. Posaconazole combined with amphotericin B, an effective therapy for a murine disseminated infection caused by Rhizopus oryzae. Antimicrob Agents Chemother 52 (2008) 3786-3788
27. Ibrahim A.S., Gebremariam T., Schwartz J.A., Edwards Jr. J.E., and Spellberg B. Posaconazole mono- or combination therapy for the treatment of murine zygomycosis. Antimicrob Agents Chemother 53 (2008) 772-775
28. Barchiesi F., Spreghini E., Santinelli A., et al. Posaconazole prophylaxis in experimental systemic zygomycosis. Antimicrob Agents Chemother 51 (2007) 73-77
29. Vyzantiadis T.A., Kioumi A., Papadakis E., et al. Rhino-cerebral zygomycosis resistant to antimycotic treatment: a case report. Mycoses 52 (2008) 87-90
30. Schlemmer F., Lagrange-Xelot M., Lacroix C., de La Tour R., Socie G., and Molina J.M. Breakthrough Rhizopus infection on posaconazole prophylaxis following allogeneic stem cell transplantation. Bone Marrow Transplant 42 (2008) 551-552
31. Verweij P.E., van der Velden W.J., Donnelly J.P., Blijlevens N.M., and Warris A. [Invasive zygomycosis in patients treated for haematological malignancies]. Nederlands tijdschrift geneeskunde 151 (2007) 2597-2602
32. Hachem R.Y., Kontoyiannis D.P., Chemaly R.F., Jiang Y., Reitzel R., and Raad I. The utility of galactomannan enzyme immunoassay and (1-3) {beta}-D-glucan in the diagnosis of invasive fungal infections: low sensitivity for Aspergillus fumigatus infection in hematologic malignancy patients. J Clin Microbiol 47 (2008) 129-133
33. Persat F., Ranque S., Derouin F., Michel-Nguyen A., Picot S., and Sulahian A. Contribution of the (1-3)-beta-D-glucan assay for diagnosis of invasive fungal infections. J Clin Microbiol 46 (2008) 1009-1013
34. Kasai M., Harrington S.M., Francesconi A., et al. Detection of a molecular biomarker for zygomycetes by quantitative PCR assays of plasma, bronchoalveolar lavage, and lung tissue in a rabbit model of experimental pulmonary zygomycosis. J Clin Microbiol 46 (2008) 3690-3702